Mozart Therapeutics Logo Skip to main content
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investment Partners
  • Science
    • Regulatory CD8 T cell network
    • Our Approach
    • Posters and Publications
  • Pipeline
    • Pipeline
    • KIR CD8 Treg Modulator
  • News
    • Press Releases
  • Careers
    • Job Opportunities
    • Values
    • Benefits
  • Contact

Press Releases

2022

May 18, 2022

Mozart Therapeutics to Present on Novel CD8 T Cell Network at the 2022 Digestive Disease Week® (DDW) Conference

May 10, 2022

Mozart Therapeutics Presents Data at IMMUNOLOGY™ 2022 Highlighting Novel CD8 Treg Network in Celiac Disease and Other Autoimmune Diseases

March 21, 2022

Mozart Therapeutics Announces Appointment of Jan Beck as Chief Operating Officer

2021

October 26, 2021

Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases

  • Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investment Partners
  • Science
    • Regulatory CD8 T cell network
    • Our Approach
    • Posters and Publications
  • Pipeline
    • Pipeline
    • KIR CD8 Treg Modulator
  • News
    • Press Releases
  • Careers
    • Job Opportunities
    • Values
    • Benefits
  • Contact
Logo© 2022 Mozart Therapeutics All rights reservedWebsite Design: Hane Chow, Inc.